Verona Pharma to Present at Upcoming Healthcare Investor Conferences

LONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announced that Company management will present at three upcoming investor conferences:

Event: 28th Annual Oppenheimer Healthcare Conference
Date: March 21, 2018
Time: 3:55 PM EDT
Location: New York, NY

Event: Needham & Co. Annual Healthcare Conference
Date: March 27, 2018
Time: 12:15 PM EDT
Location: New York, NY

Event: H.C. Wainwright Global Life Sciences Conference
Date: April 9, 2018
Time: 2:35 PM CEST
Location: Monte Carlo, Monaco

About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.